Binbin Xie

Binbin Xie

Auto-generated profile, based on publicly available information

Binbin Xie

Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
BXBinbin Xie
Binbin Xie
JWJianqin Wan
Jianqin Wan
XCXiaona Chen
Xiaona Chen
Weidong HanWeidong Han
Weidong Han
WHWang Hangxiang
Wang Hangxiang
Taxane-based chemotherapeutics are clinically available as frontline treatment regimens for cervical cancer. However, drug resistance and life-threatening toxicity impair the clinical efficacy of taxanes, so more effective and less toxic therapeutic modalities are urgently needed. Cabazitaxel has attracted increasing interest due to its potential to circumvent the drug resistance by taxanes. We previously showed that tethering docosahexaenoic acid (DHA) to cabazitaxel enabled the prodrug to self-assemble into nanoparticles in water. Despite this encouraging finding, the DHA–cabazitaxel conjugate formulation requires further optimization to enhance nanoparticle retention and tumor delivery. We here integrated this conjugate into amphiphilic poly(ethylene glycol)-block-poly(D,L-lactic acid) copolymers to assemble dCTX NPs. The nanoparticle abrogated P-glycoprotein–mediated resistance in cancer cells. In a docetaxel-resistant cervical tumor xenograft-bearing mouse model, the efficacy was augmented by the nanotherapy when compared with solution-based free drugs (i.e., docetaxel and cabazitaxel). Dose intensification of dCTX NPs markedly suppressed the tumor growth in this model. Detailed studies revealed that systemic toxicity was alleviated, and MTD of dCTX NPs was at least 3 times higher than that of free cabazitaxel in animals, which may enable dose increases for clinical studies. In conclusion, the new formulation addresses essential requirements in terms of the stability, safety, and translational capacity for initiating early-phase clinical trials.

18 May 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
DXDengyong Xu
Dengyong Xu
YCYao Chen
Yao Chen
XGXing Gao
Xing Gao
WXWeidong Xie
Weidong Xie
YWya wang
ya wang
BXBinbin Xie
Binbin Xie
Background: Many existing studies indicated that patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), tend to have the risk of low total body bone mineral density (BMD), and are more likely to have osteoporosis (OS). To determine the causal relationship between IBD and bone metabolic disorders, we herein performed a two-sample Mendelian randomization analysis (TSMR) using publicly available summary statistics.Methods: Summary statistics of total body BMD, OS and IBD were downloaded from the Open Genome-Wide Association Study (GWAS), FinnGen consortium and International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). The European and East Asian populations have consisted in this Mendelian Randomization (MR) work. A range of quality control procedures were taken to select eligible instrument SNPs closely associated with total body BMD, OS and IBD. To make the conclusions more reliable, we applied five robust analytical methods, among which the inverse variance weighting (IVW) method acted as the major method. Besides, heterogeneity, pleiotropy and sensitivity were evaluated.Results: In the European population, the genetic association of UC on total body BMD (OR=0.97, 95%CI=0.96,0.99, P<0.001) and overall IBD on total body BMD (OR=0.98, 95%CI=0.97,1.00, P=0.013) were significant, while the effect of CD on total body BMD was not significant enough (OR=0.99, 95%CI=0.98,1.00, P=0.085). All of UC, CD and overall IBD can be the genetic risk factor of having OS with pathological fracture (UC: OR=1.13, 95%CI=1.02,1.26, P=0.024, CD: OR=1.14, 95%CI=1.05,1.25, P=0.003, overall IBD: OR=1.13, 95%CI=1.02,1.24, P=0.015). In East Asian groups, only CD had a causal relationship with OS (OR=1.04, 95% CI=1.01,1.07, P=0.019).Conclusion: Our study revealed genetically predicted associations between IBD on total body BMD and OS in European and East Asian populations. This work supplemented the results of previous retrospective studies and demonstrated the necessity of BMD monitoring in patients with IBD.

3 April 2023
Verified
Other
Open access
BXBinbin Xie
Binbin Xie
JWJianqin Wan
Jianqin Wan
XCXiaona Chen
Xiaona Chen
WHWeidong Han
Weidong Han
WHWang Hangxiang
Wang Hangxiang
Taxane-based chemotherapeutics are clinically available as frontline treatment regimens for cervical cancer. However, drug resistance and life-threatening toxicity impair the clinical efficacy of taxanes, so more effective and less toxic therapeutic modalities are urgently needed. Cabazitaxel has attracted increasing interest due to its potential to circumvent the drug resistance by taxanes. We previously showed that tethering docosahexaenoic acid (DHA) to cabazitaxel enabled the prodrug to self-assemble into nanoparticles in water. Despite this encouraging finding, the DHA–cabazitaxel conjugate formulation requires further optimization to enhance nanoparticle retention and tumor delivery. We here integrated this conjugate into amphiphilic poly(ethylene glycol)-block-poly(D,L-lactic acid) copolymers to assemble dCTX NPs. The nanoparticle abrogated P-glycoprotein–mediated resistance in cancer cells. In a docetaxel-resistant cervical tumor xenograft-bearing mouse model, the efficacy was augmented by the nanotherapy when compared with solution-based free drugs (i.e., docetaxel and cabazitaxel). Dose intensification of dCTX NPs markedly suppressed the tumor growth in this model. Detailed studies revealed that systemic toxicity was alleviated, and MTD of dCTX NPs was at least 3 times higher than that of free cabazitaxel in animals, which may enable dose increases for clinical studies. In conclusion, the new formulation addresses essential requirements in terms of the stability, safety, and translational capacity for initiating early-phase clinical trials.

3 April 2023
Verified
Other
Open access
BXBinbin Xie
Binbin Xie
JWJianqin Wan
Jianqin Wan
XCXiaona Chen
Xiaona Chen
WHWeidong Han
Weidong Han
WHWang Hangxiang
Wang Hangxiang
Supplementary Table S1. Hematology measurements for the mice after the treatment with saline, cabazitaxel and dCTX NPs. The blood samples were collected on day 0, 6, 11, and 15 post-administration. The data are presented as the means {plus minus} SD (n = 5).

3 April 2023
Verified
Other
Open access
BXBinbin Xie
Binbin Xie
JWJianqin Wan
Jianqin Wan
XCXiaona Chen
Xiaona Chen
WHWeidong Han
Weidong Han
WHWang Hangxiang
Wang Hangxiang
Supplementary methods for nanonparticle characterization, cell assays and histological analyses of tumors.

3 April 2023
Verified
Other
Open access
BXBinbin Xie
Binbin Xie
JWJianqin Wan
Jianqin Wan
XCXiaona Chen
Xiaona Chen
WHWeidong Han
Weidong Han
WHWang Hangxiang
Wang Hangxiang
Supplementary Figure S2. The cytotoxicity of dCTX NPs compared with cabazitaxel against cancer cell lines in vitro. Analysis (A) and quantification (B) of apoptosis of HeLa and A549 cells after the treatment with dCTX NPs for 48 h. The drug concentrations used to treat HeLa and A549 cells were 16 and 4 nM, respectively.